全文获取类型
收费全文 | 1029032篇 |
免费 | 80092篇 |
国内免费 | 5369篇 |
专业分类
耳鼻咽喉 | 13373篇 |
儿科学 | 34815篇 |
妇产科学 | 28922篇 |
基础医学 | 148021篇 |
口腔科学 | 28334篇 |
临床医学 | 94114篇 |
内科学 | 196324篇 |
皮肤病学 | 23317篇 |
神经病学 | 80095篇 |
特种医学 | 39840篇 |
外国民族医学 | 320篇 |
外科学 | 152954篇 |
综合类 | 32149篇 |
一般理论 | 390篇 |
预防医学 | 80581篇 |
眼科学 | 23427篇 |
药学 | 76178篇 |
47篇 | |
中国医学 | 4675篇 |
肿瘤学 | 56617篇 |
出版年
2019年 | 8325篇 |
2018年 | 11557篇 |
2017年 | 9569篇 |
2016年 | 10353篇 |
2015年 | 12288篇 |
2014年 | 16675篇 |
2013年 | 24308篇 |
2012年 | 32130篇 |
2011年 | 34122篇 |
2010年 | 20964篇 |
2009年 | 19522篇 |
2008年 | 31108篇 |
2007年 | 32824篇 |
2006年 | 33120篇 |
2005年 | 31649篇 |
2004年 | 30690篇 |
2003年 | 29776篇 |
2002年 | 28473篇 |
2001年 | 48206篇 |
2000年 | 48823篇 |
1999年 | 40758篇 |
1998年 | 11013篇 |
1997年 | 9943篇 |
1996年 | 9793篇 |
1995年 | 9984篇 |
1994年 | 9298篇 |
1993年 | 8579篇 |
1992年 | 32349篇 |
1991年 | 31586篇 |
1990年 | 31092篇 |
1989年 | 29941篇 |
1988年 | 27209篇 |
1987年 | 27366篇 |
1986年 | 25456篇 |
1985年 | 24628篇 |
1984年 | 18385篇 |
1983年 | 15482篇 |
1982年 | 9259篇 |
1981年 | 8342篇 |
1979年 | 16834篇 |
1978年 | 12193篇 |
1977年 | 10284篇 |
1976年 | 9706篇 |
1975年 | 10133篇 |
1974年 | 12283篇 |
1973年 | 11818篇 |
1972年 | 10861篇 |
1971年 | 10092篇 |
1970年 | 9361篇 |
1969年 | 8707篇 |
排序方式: 共有10000条查询结果,搜索用时 5 毫秒
1.
Nicholas B. Abt Lauren E. Miller Tara E. Mokhtari Derrick T. Lin Jeremy D. Richmon Daniel G. Deschler Mark A. Varvares Sidharth V. Puram 《American journal of otolaryngology》2021,42(6):103070
ObjectiveTo determine prognostic factors and survival patterns for different treatment modalities for nasal cavity (NC) and paranasal sinus (PS) mucosal melanoma (MM).MethodsPatients from 1973 to 2013 were analyzed using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and multivariable cox proportional hazard modeling were used for survival analyses.ResultsOf 928 cases of mucosal melanoma (NC = 632, PS = 302), increasing age (Hazard Ratio [HR]:1.05/year, p < 0.001), T4 tumors (HR: 1.81, p = 0.02), N1 status (HR: 6.61, p < 0.001), and PS disease (HR: 1.50, p < 0.001) were associated with worse survival. Median survival length was lower for PS versus NC (16 versus 26 months, p < 0.001). Surgery and surgery + radiation therapy (RT) improved survival over non-treatment or RT alone (p < 0.001). Adding RT to surgery did not yield a survival difference compared with surgery alone (p = 0.43). Five-year survival rates for surgery and surgery + RT were similar, at 27.7% and 25.1% (p = 0.43).ConclusionSurgery increased survival significantly over RT alone. RT following surgical resection did not improve survival. 相似文献
2.
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
5.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
6.
目的探讨C型凝集素受体Dectin-2在烟曲霉菌感染中的作用及机制。方法用紫外线灭活的烟曲霉菌膨胀态分生孢子刺激野生型(wild type, WT)和Dectin-2缺失(Clec4n-/-)小鼠骨髓来源的巨噬细胞(bone marrow derived macrophages, BMDMs)。刺激20min及40min后,利用Western印迹法检测BMDMs中脾酪氨酸激酶(spleen tyrosine kinase, Syk)和核转录因子κB抑制因子(inhibitor-κB, IκBα)的磷酸化水平。刺激16h后,利用酶联免疫吸附法(enzyme-linked immunosorbent assay, ELISA)检测BMDMs细胞上清液中IL-6、TNF-α和IL-12p40的水平。另一方面,利用压舌感染的方法在WT和Clec4n-/-小鼠中构建烟曲霉菌肺部感染模型。感染2d后,统计小鼠整个肺脏荷菌量,并检测肺脏匀浆液中IL-6和IL-12p40水平。结果体外试验提示,烟曲霉菌刺激后,Dectin-2缺失的BMDMs中Syk和IκBα的磷酸化水平及IL-6、TNF-α和IL-12p40水平显著下降(P<0.05)。体内试验发现,烟曲霉菌感染后,Dectin-2缺失小鼠中肺脏荷菌量显著升高(P<0.05),肺脏匀浆液内IL-6、IL-12p40水平显著降低(P<0.05)。结论C型凝集素受体Dectin-2激活烟曲霉菌诱导的NF-κB信号通路并介导促炎细胞因子的产生,可在小鼠肺烟曲霉菌病动物模型中发挥保护性作用。 相似文献
7.
目的 探究产科高危患者的抢救中实施护理应急预案联合责任制护理的价值.方法 选取2018年9月至2020年6月厦门市妇幼保健院收治的66例产科高危患者作为研究对象,按照随机数字表法分为A组(33例)与B组(33例).A组采用常规护理,B组采用护理应急预案联合责任制护理.比较两组的疾病知识掌握度、护理质量、满意度、母乳喂养情况.结果 B组的疾病知识总掌握度高于A组,差异有统计学意义(P<0.05).B组的护理质量评分高于A组,差异有统计学意义(P<0.05).B组的护理总满意度高于A组,差异有统计学意义(P<0.05).B组的母乳喂养成功率高于A组,差异有统计学意义(P<0.05).B组的泌乳量多于A组,差异有统计学意义(P<0.05).B组的泌乳起始时间短于A组,差异有统计学意义(P<0.05).结论 于产科高危患者的抢救中,实施护理应急预案联合责任制护理可提高患者的疾病知识掌握度、护理质量、满意度以及母乳喂养成功率,并可促进泌乳. 相似文献
8.
9.
目的 评价接种1剂水痘疫苗在学校水痘暴发疫情中的保护效果(vaccine effectiveness, VE)。方法 采用1:2配对病例对照研究,收集中山市2013—2021年水痘暴发疫情调查资料,将病例数≥5例的班的所有病例(共942例)作为病例组,按1:2的比例选取同班、同年龄(±1岁)、同性别的1 884名健康儿童作为对照组,调查其水痘疫苗接种史,采用条件logistic回归分析水痘疫苗保护效果。结果 共调查3~14岁儿童2 826名,儿童接种1剂水痘疫苗的保护效果为58%(95%CI:50%~66%),3~5岁、6~14岁儿童接种1剂水痘疫苗保护效果分别为75%(95%CI:62%~83%)和51%(95%CI:40%~61%)。儿童接种1剂后≤2年、3~5年、6~8年、≥9年的保护效果分别为78%(95%CI:66%~86%)、66%(95%CI:57%~74%)、51%(95%CI:36%~62%)、23%(95%CI:-11%~46%)。儿童接种1剂水痘疫苗的保护效果随接种后时间的延长而降低(趋势χ2=13.071,P<0.001)。结论 儿童接种1剂水痘疫苗有助于防控水痘暴发疫情,但其保护效果随接种后时间的延长而降低,难以阻断水痘传播。建议儿童及时接种2剂水痘疫苗,以预防学校水痘暴发疫情。 相似文献